Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Manfidokimab - Akeso Biopharma

Next Previous
Drug Profile

Manfidokimab - Akeso Biopharma

Alternative Names: AK-120 - Akeso Biopharma; IL-4R monoclonal antibody

Latest Information Update: 01 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Class Anti-inflammatories; Antiasthmatics; Antibodies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Discontinued Asthma; Eosinophilic oesophagitis

Most Recent Events

  • 25 Aug 2025 Akeso announces intention to submit NDA of manfidokimab for Atopic dermatitis
  • 25 Aug 2025 Efficacy data from a phase III trial in Atopic dermatitis released by Akeso Biopharma
  • 26 Feb 2025 Akeso Biopharma terminates a Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly) in USA, New Zealand and Australia (SC) due to clinical study and development strategy adjustment (NCT05048056)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top